BioHarvest Sciences Inc. announced on February 18, 2025, that its flagship red grape cell composition, commercially known as VINIA, has exceeded $50 million USD in cumulative sales. The majority of these sales have occurred since its launch in the U.S. less than four years ago in May 2021.
As of February 16, 2025, VINIA also achieved a milestone of over 50,000 active U.S. users on recurring subscription packages. The product has garnered approximately 8,000 customer reviews with an average rating of 4.8/5, reflecting strong consumer satisfaction and efficacy.
In response to this growth and confidence in the business trajectory, BioHarvest plans to expand its production capacity by four times. This expansion includes building a new 100-ton per year production facility, which is expected to be operational in late 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.